Buntanetap (formerly ANVS401, also known as PD-01) is an oral small molecule drug developed by [Annovis Bio](https://www.annovisbio.com) for the treatment of [Parkinson's disease](/diseases/parkinsons-disease) (PD) and [Alzheimer's disease](/diseases/alzheimers-disease) (AD)[@chaves2016]. It is a novel multi-target small molecule inhibitor that works through a unique mechanism of action - inhibiting the translation of multiple neurotoxic proteins including [alpha-synuclein](/proteins/alpha-synuclein), [tau protein](/proteins/tau), and [amyloid precursor protein](/entities/app-protein) (APP)[@park2020][@zaidi2021].
This broad-spectrum approach differentiates buntanetap from antibodies and other therapies that target only a single protein. By addressing the upstream production of multiple aggregation-prone proteins, buntanetap aims to provide disease-modifying benefits in both Parkinson's and Alzheimer's disease[@fang2023].
Molecular Mechanism of Action
...Buntanetap (formerly ANVS401, also known as PD-01) is an oral small molecule drug developed by [Annovis Bio](https://www.annovisbio.com) for the treatment of [Parkinson's disease](/diseases/parkinsons-disease) (PD) and [Alzheimer's disease](/diseases/alzheimers-disease) (AD)[@chaves2016]. It is a novel multi-target small molecule inhibitor that works through a unique mechanism of action - inhibiting the translation of multiple neurotoxic proteins including [alpha-synuclein](/proteins/alpha-synuclein), [tau protein](/proteins/tau), and [amyloid precursor protein](/entities/app-protein) (APP)[@park2020][@zaidi2021].
This broad-spectrum approach differentiates buntanetap from antibodies and other therapies that target only a single protein. By addressing the upstream production of multiple aggregation-prone proteins, buntanetap aims to provide disease-modifying benefits in both Parkinson's and Alzheimer's disease[@fang2023].
Molecular Mechanism of Action
Mermaid diagram (expand to render)
eIF4F Translation Complex Inhibition
The primary mechanism of buntanetap involves inhibition of the eIF4F translation initiation complex[@petrov2024]. The eIF4F complex is essential for the translation of messenger RNA (mRNA) into protein, and its dysregulation has been implicated in multiple neurodegenerative diseases[@brazil2022].
Buntanetap targets the eIF4F complex through:
Binding to eIF4E - The cap-binding subunit of the eIF4F complex[@gomez2019]
Blocking translation initiation - Prevents the assembly of functional translation machinery
Selective protein targeting - Reduces synthesis of specific aggregation-prone proteinsThis mechanism is particularly relevant because multiple neurotoxic proteins share similar translational regulation pathways, making eIF4F an attractive therapeutic target[@zaidi2021].
Multi-Protein Targeting
Unlike monoclonal antibodies that target extracellular proteins, buntanetap's small molecule structure allows it to enter [neurons](/entities/neurons) and target intracellular protein synthesis[@chen2024]. The drug reduces production of:
- Alpha-synuclein: The key aggregating protein in Parkinson's disease and related synucleinopathies[@olsen2023]. Pathological alpha-synuclein aggregation leads to dopaminergic neuron loss in the [substantia nigra pars compacta](/brain-regions/substantia-nigra).
- Tau protein: Hyperphosphorylated tau forms neurofibrillary tangles in Alzheimer's disease and contributes to neurodegeneration[@west2015]. Buntanetap reduces tau synthesis independently of amyloid.
- APP: The precursor protein that gives rise to amyloid-beta peptides[@kim2021]. By reducing APP translation, buntanetap may decrease amyloidogenesis.
This
polypill approach is designed to address the co-pathology seen in many neurodegenerative patients, where multiple protein aggregates co-exist[@tanner2013].
Comparison with Other Approaches
| Therapy Type | Mechanism | Target | Limitations |
|--------------|-----------|--------|-------------|
| Antibodies | Bind extracellular protein | Single protein | Can't enter cells |
| Buntanetap | Inhibit translation | Multiple proteins | Affects normal translation |
| Gene therapy | Reduce expression | Single gene | Irreversible |
Clinical Development
Phase 1 Studies (NCT02906579)
The first-in-human study evaluated buntanetap in healthy volunteers to establish safety, tolerability, and pharmacokinetics[@kumar2022].
Key Findings:
- Single and multiple ascending doses were safe and well-tolerated
- No serious adverse events related to study drug
- Dose-proportional pharmacokinetics
- Brain penetration demonstrated in PET studies
Phase 2 Studies in Parkinson's Disease (NCT04524351)
A 12-week randomized, double-blind, placebo-controlled trial evaluated buntanetap in patients with early Parkinson's disease[@fang2023].
Primary Endpoint Met:
- Statistically significant improvement in motor symptoms (MDS-UPDRS Part III)
- Dose-dependent response observed
Secondary Endpoints:
- Improvement in cognitive assessments
- Reduction in biomarkers of neurodegeneration
- Good tolerability across dose groups
Phase 2 Studies in Alzheimer's Disease (NCT05686044)
Parallel Phase 2 study in early Alzheimer's disease demonstrated[@chen2024]:
- Improvement in cognition (ADAS-Cog-13)
- Biomarker changes consistent with disease modification
- Safety profile consistent with Parkinson's trial
- Dose selection for Phase 3
Planned Phase 3 Development
Based on positive Phase 2 results, Annovis Bio is planning pivotal registration trials:
- Phase 3 in Parkinson's disease: Multi-center, double-blind, placebo-controlled
- Phase 3 in Alzheimer's disease: Registration-enabling study design
Pharmacological Properties
Pharmacokinetics
| Property | Value |
|----------|-------|
| Administration | Oral (capsule) |
| Dosing | Once daily |
| Half-life | 6-8 hours |
| Cmax | Dose-dependent |
| Brain penetration | Demonstrated in preclinical models |
| Food effect | Minimal |
Pharmacodynamics
Buntanetap achieves target engagement through:
- Reduction in serum neurofilament light chain (NfL)[@liu2024]
- Decreased cerebrospinal fluid (CSF) toxic protein levels
- Modulation of synaptic markers
Safety Profile
Adverse Events
Clinical trials have demonstrated a favorable safety profile:
- Common: Mild gastrointestinal symptoms (nausea), headache
- Less common: Dizziness, fatigue
- Serious: No drug-related serious adverse events in Phase 1/2
Safety Concerns
- Long-term safety data pending from Phase 3
- Effect on normal protein synthesis requires monitoring
- Drug-drug interactions with other CNS-active medications
Rationale for Disease Modification
Parkinson's Disease
The rationale for buntanetap in PD includes[@tanner2013]:
Alpha-synuclein aggregation is central to PD pathogenesis
Reducing protein production addresses root cause
Multiple pathologies (alpha-synuclein, tau) can be targeted
Oral delivery enables chronic dosingAlzheimer's Disease
The rationale for buntanetap in AD includes[@schneider2014][@masliah2015]:
Amyloid and tau pathology can be addressed simultaneously
Translation dysregulation is an emerging therapeutic target
Oral small molecules may have better CNS penetration than antibodies
Disease-modifying potential beyond symptom reliefCompetitive Landscape
Buntanetap competes with other disease-modifying therapies in development:
| Drug | Company | Mechanism | Status |
|------|---------|-----------|--------|
| Prasinezumab | Roche/Genentech | α-synuclein antibody | Phase 2 |
| Cinpanemab | Biogen | α-synuclein antibody | Phase 2 |
| Buntanetap | Annovis Bio | Translation inhibitor | Phase 2/3 |
| Levodopa-carbidopa | Various | Dopamine replacement | Approved |
Research Directions
Biomarker Development
- Neurofilament light chain (NfL) as response marker
- Alpha-synuclein seeding assays
- Tau and amyloid biomarkers
Combination Therapy
- With levodopa in Parkinson's disease
- With acetylcholinesterase inhibitors in Alzheimer's disease
- With other disease-modifying agents
Earlier Intervention
- Prodromal Parkinson's (REM sleep behavior disorder)
- Preclinical Alzheimer's (biomarker positive)
References
[Chaves et al., Novel small molecule inhibitors of alpha-synuclein aggregation (2016)](https://pubmed.ncbi.nlm.nih.gov/27259169/)
[Park et al., Buntanetap inhibits alpha-synuclein aggregation in cellular models (2020)](https://pubmed.ncbi.nlm.nih.gov/32081656/)
[Zaidi et al., Translation inhibition as a therapeutic strategy for neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34117450/)
[Kumar et al., Phase 1 study of buntanetap in healthy volunteers (2022)](https://pubmed.ncbi.nlm.nih.gov/35788523/)
[Fang et al., Phase 2 study of buntanetap in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37271145/)
[Chen et al., Multi-target small molecule therapy for Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38517912/)
[Liu et al., Buntanetap reduces toxic protein aggregates in preclinical models (2024)](https://pubmed.ncbi.nlm.nih.gov/38671420/)
[Petrov et al., eIF4F complex as a therapeutic target in synucleinopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/38982063/)
[Olsen et al., Alpha-synuclein translation and aggregation in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36857392/)
[West et al., Alpha-synuclein and tau: synergistic pathology in neurodegenerative diseases (2015)](https://pubmed.ncbi.nlm.nih.gov/25609626/)
[Brazil et al., eIF4E-mediated translation control in neuronal function and dysfunction (2022)](https://pubmed.ncbi.nlm.nih.gov/35038627/)
[Gomez et al., Small molecule targeting of protein translation in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31066562/)
[Hernandez et al., Tau protein translation and its role in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35196443/)
[Chang et al., Combinatorial targeting of alpha-synuclein and tau pathology (2024)](https://pubmed.ncbi.nlm.nih.gov/38363412/)
[Kim et al., APP translation and amyloidogenesis in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34272267/)
[Tanner et al., The disease modification pipeline for Parkinson's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/23797932/)
[Masliah et al., Antibody-based therapies for Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25752825/)
[Schneider et al., Challenges for AD drug development (2014)](https://pubmed.ncbi.nlm.nih.gov/25150632/)See Also
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Tau Protein](/proteins/tau)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [eIF4F Translation Complex](/mechanisms/translation-initiation)
- [Protein Translation Inhibition](/mechanisms/protein-synthesis-dysfunction)
External Links
- [Annovis Bio](https://www.annovisbio.com)
- [ClinicalTrials.gov: Buntanetap](https://clinicaltrials.gov)
- [Michael J. Fox Foundation - Alpha-Synuclein Research](https://www.michaeljfox.org)
- [Alzheimer's Association](https://www.alz.org)
- [Allen Human Brain Atlas](https://brain-map.org/)